Emergence of ghrelin as a treatment for cachexia syndromes

Nutrition

Volumn 24, Issue 9, 2008, Pages 806-814

  DeBoer, Mark Daniel ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Agouti peptide; Muscle wasting; Neuropeptide

Indexed keywords

ANAMORELIN; BIM 28125; BIM 28131; GHRELIN; GHRP 1; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONIST; HEXARELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; NEUROPEPTIDE Y; PLACEBO; PRALMORELIN; RC 1291; UNCLASSIFIED DRUG;

APPETITE; BODY MASS; CACHEXIA; CANCER CHEMOTHERAPY; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; HEART FAILURE; HUMAN; INFLAMMATION; NEOPLASM; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APPETITE REGULATION; CACHEXIA; CHRONIC DISEASE; GHRELIN; HEART FAILURE; HUMANS; KIDNEY DISEASES; MICE; NEOPLASMS; RATS; SYNDROME;

AGOUTI; ANIMALIA;

EID: 49749111114     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2008.06.013     Document Type: Review

References (42)

1. Tisdale M.J. Biology of cachexia. J Natl Cancer Inst 89 (1997) 1763-1773
2. DeBoer M.D., and Marks D.L. Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab 17 (2006) 199-204
3. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
4. Cummings D.E., Weigle D.S., Frayo R.S., Breen P.A., Ma M.K., Dellinger E.P., and Purnell J.Q. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346 (2002) 1623-1630
5. Akamizu T., Takaya K., Irako T., Hosoda H., Teramukai S., Matsuyama A., et al. Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 150 (2004) 447-455
6. Granado M., Priego T., Martin A.I., Villanua M.A., and Lopez-Calderon A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 288 (2005) E486-E492
7. Sun Y., Wang P., Zheng H., and Smith R.G. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 101 (2004) 4679-4684
8. Wang Z., Wang W., Qiu W., Fan Y., Zhao J., Wang Y., and Zheng Q. Involvement of ghrelin-growth hormone secretagogue receptor system in pathoclinical profiles of digestive system cancer. Acta Biochim Biophys Sin (Shanghai) 39 (2007) 992-998
9. Sun Y., Ahmed S., and Smith R.G. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23 (2003) 7973-7981
10. Asakawa A., Inui A., Kaga T., Katsuura G., Fujimiya M., Fujino M.A., and Kasuga M. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52 (2003) 947-952
11. DeBoer M.D. Melanocortin interventions in cachexia: how soon from bench to bedside?. Curr Opin Clin Nutr Metab Care 10 (2007) 457-462
12. Willesen M.G., Kristensen P., and Romer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 70 (1999) 306-316
13. Chen H.Y., Trumbauer M.E., Chen A.S., Weingarth D.T., Adams J.R., Frazier E.G., et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti related protein. Endocrinology 145 (2004) 2607-2612
14. Faulconbridge L.F., Cummings D.E., Kaplan J.M., and Grill H.J. Hyperphagic effects of brainstem ghrelin administration. Diabetes 52 (2003) 2260-2265
15. Tschop M., Statnick M.A., Suter T.M., and Heiman M.L. GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology 143 (2002) 558-568
16. Tisdale M.J. Cachexia in cancer patients. Nat Rev Cancer 2 (2002) 862-871
17. Shimizu Y., Nagaya N., Isobe T., Imazu M., Okumura H., Hosoda H., et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 9 (2003) 774-778
18. Garcia J.M., Garcia-Touza M., Hijazi R.A., Taffet G., Epner D., Mann D., et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90 (2005) 2920-2926
19. Hanada T., Toshinai K., Kajimura N., Nara-Ashizawa N., Tsukada T., Hayashi Y., et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 301 (2003) 275-279
20. Wang W., Andersson M., Iresjo B.M., Lonnroth C., and Lundholm K. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int J Oncol 28 (2006) 1393-1400
21. DeBoer M.D., Zhu X.X., Levasseur P., Meguid M.M., Suzuki S., Inui A., et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 148 (2007) 3004-3012
22. Neary N.M., Small C.J., Wren A.M., Lee J.L., Druce M.R., Palmieri C., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89 (2004) 2832-2836
23. Garcia J.M., Graham C., Kumor K., and Polvino W. A Phase II, randomized, placebo-controlled, double blind study of the efficacy and safety of RC-1291 for the treatment of cancer-cachexia [abstract]. BR. J Clin Oncol 25 18S (2007) S25
24. Strasser F., Lutz T.A., Maeder M.T., Thuerlimann B., Bueche D., Tschop M., et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 98 (2008) 300-308
25. Orme S.M., McNally R.J., Cartwright R.A., and Belchetz P.E. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83 (1998) 2730-2734
26. Qureshi A.R., Alvestrand A., Divino-Filho J.C., Gutierrez A., Heimburger O., Lindholm B., and Bergstrom J. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13 suppl 1 (2002) S28-S36
27. Yoshimoto A., Mori K., Sugawara A., Mukoyama M., Yahata K., Suganami T., et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 13 (2002) 2748-2752
28. DeBoer M.D., Zhu X., Levasseur P.R., Inui A., Hu Z., Han G., et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149 (2008) 827-835
29. Wynne K., Giannitsopoulou K., Small C.J., Patterson M., Frost G., Ghatei M.A., et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 16 (2005) 2111-2118
30. Anker S.D., Ponikowski P., Varney S., Chua T.P., Clark A.L., Webb-Peploe K.M., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997) 1050-1053
31. Nagaya N., Uematsu M., Kojima M., Date Y., Nakazato M., Okumura H., et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 104 (2001) 2034-2038
32. Itoh T., Nagaya N., Yoshikawa M., Fukuoka A., Takenaka H., Shimizu Y., et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 879-882
33. Nagaya N., Uematsu M., Kojima M., Ikeda Y., Yoshihara F., Shimizu W., et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104 (2001) 1430-1435
34. Xu X.B., Pang J.J., Cao J.M., Ni C., Xu R.K., Peng X.Z., et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol 289 (2005) H1643-H1651
35. Nagaya N., Itoh T., Murakami S., Oya H., Uematsu M., Miyatake K., and Kangawa K. Treatment of cachexia with ghrelin in patients with COPD. Chest 128 (2005) 1187-1193
36. Nagaya N., Moriya J., Yasumura Y., Uematsu M., Ono F., Shimizu W., et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110 (2004) 3674-3679
37. Liu Y.L., Malik N.M., Sanger G.J., and Andrews P.L. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol 58 (2006) 326-333
38. Garcia J.M., Cata J.P., Dougherty P.M., and Smith R.G. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 149 (2008) 455-460
39. Toshinai K., Mondal M.S., Shimbara T., Yamaguchi H., Date Y., Kangawa K., and Nakazato M. Ghrelin stimulates growth hormone secretion and food intake in aged rats. Mech Ageing Dev 128 (2007) 182-186
40. Balasubramaniam A., Wood S., Joshi R., Su C., Friend L.A., Sheriff S., and James J.H. Ghrelin stimulates food intake and growth hormone release in rats with thermal injury: synthesis of ghrelin. Peptides 27 (2006) 1624-1631
41. Filigheddu N., Gnocchi V.F., Coscia M., Cappelli M., Porporato P.E., Taulli R., et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell 18 (2007) 986-994
42. Baldanzi G., Filigheddu N., Cutrupi S., Catapano F., Bonissoni S., Fubini A., et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159 (2002) 1029-1037